[en] Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues(1-3), often with serious pathological consequences. Non-neuropathic systemic amyloidosis (4-6) is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody(7-9) raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases.
Tan, S. Y. & Pepys, M. Amyloidosis. Histopathology 25, 403-414 (1994).
Koo, E. H., Lansbury, P. T. Jr & Kelly, J. W. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc. Natl Acad. Sci. USA 96, 9989-9990 (1999).
Dobson, C. M. The structural basis of protein folding and its links with human disease. Phil. Trans. R. Soc. Lond. B 356, 133-145 (2001).
Pepys, M. B. et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362, 553-557 (1993).
Valleix, S. et al. Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int. 61, 907-912 (2002).
Yazaki, M., Farrell, S. A. & Benson, M. D. A novel lysozyme mutation Phe57IIe associated with hereditary renal amyloidosis. Kidney Int. 63, 1652-1657 (2003).
Dumoulin, M. et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 11, 500-515 (2002).
Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446-448 (1993).
Muyldermans, S. Single domain camel antibodies: current status. J. Biotechnol. 74, 277-302 (2001).
Booth, D. R. et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793 (1997).
Canet, D. et al. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nature Struct. Biol. 9, 308-315 (2002).
Schenk, D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nature Rev. Neurosci. 3, 824-828 (2002).
Peretz, D. et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001).
White, A. R. et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83 (2003).
Harper, J. D. & Lansbury, P. T. Jr Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407 (1997).
Klunk, W. E., Pettegrew, J. W. & Abraham, D. J. Two simple methods for quantifying low-affinity dyesubstrate binding. J. Histochem. Cytochem. 37, 1293-1297 (1989).
Colon, W. & Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660 (1992).
Morozova-Roche, L. A. et al. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J. Struct. Biol. 130, 339-351 (2000).
Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739 (1997).
Aguzzi, A., Glatzel, M., Montrasio, F., Prinz, M. & Heppner, F. L. Interventional strategies against prion diseases. Nature Rev. Neurosci. 2, 745-749 (2001).
Wolfe, M. S. Therapeutic strategies for Alzheimer's disease. Nature Rev. Drug Discov. 1, 859-866 (2002).
Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259 (2002).
Dobson, C. M. Protein folding and disease: a view from the first Horizon Symposium. Nature Rev. Drug Discov. 2, 154-160 (2003).
May, B. C. et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl Acad. Sci. USA 100, 3416-3421 (2003).
McCammon, M. G. et al. Screening transthyretin amyloid fibril inhibitors. Characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure (Cambridge) 10, 851-863 (2002).
Hammarstrom, P., Wiseman, R. L., Powers, E. T. & Kelly, J. W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299, 713-716 (2003).
Branden, C. & Tooze, J. Introduction to Protein Structure (Garland, New York, 1999).
Spencer, A. et al. Expression, purification, and characterization of the recombinant calcium-binding equine lysozyme secreted by the filamentous fungus Agpergillus niger: Comparisons with the production of hen and human lysozymes. Protein Expr. Purif. 16, 171-180 (1999).
Ohkubo, T., Taniyama, Y. & Kikuchi, M. 1H and 15N NMR study of human lysozyme. J. Biochem. (Tokyo) 110, 1022-1029 (1991).
Koradi, R., Billeter, M. & Wuthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 51-55 (1996).
